Perfromance Wealth Partners’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$922K Sell
25,090
-319
-1% -$15.1K 0.03% 87
2025
Q4
$1.29M Sell
25,409
-1,898
-7% -$97.1K 0.04% 70
2025
Q3
$1.52M Sell
27,307
-992
-4% -$58.1K 0.04% 60
2025
Q2
$1.95M Sell
28,299
-4,112
-13% -$280K 0.06% 51
2025
Q1
$2.25M Buy
32,411
+458
+1% +$37.8K 0.08% 44
2024
Q4
$2.75M Sell
31,953
-127,184
-80% -$13.8M 0.09% 36
2024
Q3
$18.9M Buy
159,137
+8,419
+6% +$1.12M 0.65% 18
2024
Q2
$21.5M Buy
150,718
+87,047
+137% +$11.5M 0.79% 17
2024
Q1
$8.18M Buy
63,671
+13,074
+26% +$1.56M 0.34% 23
2023
Q4
$5.23M Buy
50,597
+9,961
+25% +$985K 0.23% 34
2023
Q3
$3.7M Buy
40,636
+374
+0.9% +$32.9K 0.18% 48
2023
Q2
$3.22M Buy
40,262
+2,600
+7% +$212K 0.15% 49
2023
Q1
$3M Buy
37,662
+200
+0.5% +$14.2K 0.15% 49
2022
Q4
$2.54M Buy
37,462
+2,562
+7% +$150K 0.15% 48
2022
Q3
$1.74M Buy
34,900
+3,200
+10% +$171K 0.1% 50
2022
Q2
$1.77M Buy
31,700
+1,684
+6% +$93.4K 0.1% 52
2022
Q1
$1.67M Buy
30,016
+2,498
+9% +$128K 0.07% 58
2021
Q4
$1.54M Buy
+27,518
New +$1.49M 0.06% 65

Other funds holding NVO

Perfromance Wealth Partners's NVO Position: Q1 2026 in Review

Perfromance Wealth Partners reduced its Novo Nordisk (NVO) stake by 1.3% in Q1 2026, selling an estimated $15.1K and leaving 25,090 shares worth $922K. The position accounts for 0.03% of the portfolio, ranked #87.

Perfromance Wealth Partners first reported a position in NVO in Q4 2021 and has held it in 18 quarters since. The position peaked at $21.5M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Perfromance Wealth Partners held 25,090 shares of Novo Nordisk worth $922K as of Q1 2026.
  • Perfromance Wealth Partners sold 319 Novo Nordisk shares in Q1 2026, an estimated $15.1K.
  • Novo Nordisk made up 0.03% of Perfromance Wealth Partners's portfolio in Q1 2026, its #87 holding.
  • Perfromance Wealth Partners first reported a position in Novo Nordisk in Q4 2021 and has held it in 18 quarters since.
  • Perfromance Wealth Partners's Novo Nordisk position peaked at $21.5M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Perfromance Wealth Partners's 13F filing for Q1 2026, filed 10 Apr 2026.